相似文献
1
Mobilizing Primary Care Against the Opioid Crisis in the Post X-Waiver Era.
J Gen Intern Med. 2023 Dec;38(16):3618-3620. doi: 10.1007/s11606-023-08382-2. Epub 2023 Aug 31.
2
Removing One Barrier to Opioid Use Disorder Treatment: Is It Enough?
JAMA. 2021 Mar 23;325(12):1147-1148. doi: 10.1001/jama.2021.0958.
3
The Impact of Completing X-Waiver Training and Clinical Addiction Exposure on Internal Medicine Residents Treating Patients With Opioid Use Disorder.
Subst Use Addctn J. 2024 Jul;45(3):356-366. doi: 10.1177/29767342231221004. Epub 2024 Jan 7.
4
What the X? Understanding changes in buprenorphine prescribing regulation.
J Am Assoc Nurse Pract. 2024 Mar 1;36(3):147-150. doi: 10.1097/JXX.0000000000000942.
5
Revisiting emergency department use of buprenorphine as a primary analgesic in nonopioid use disorder patients post-X-waiver.
Acad Emerg Med. 2023 Dec;30(12):1272-1274. doi: 10.1111/acem.14749. Epub 2023 May 30.
6
The Implementation of a Clinic-Based Opioid Review Board to Address High-Risk Opioid Prescribing in Primary Care.
Ann Fam Med. 2021 Nov-Dec;19(6):563. doi: 10.1370/afm.2738.
7
Treating Adolescent Opioid Use Disorder in Primary Care.
JAMA Pediatr. 2024 Apr 1;178(4):414-416. doi: 10.1001/jamapediatrics.2023.6493.
8
A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions.
Am J Emerg Med. 2021 Oct;48:316-322. doi: 10.1016/j.ajem.2021.06.065. Epub 2021 Jul 5.
9
Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program.
J Subst Abuse Treat. 2022 Jan;132:108452. doi: 10.1016/j.jsat.2021.108452. Epub 2021 Apr 30.
10
Use and misuse of opioid agonists in opioid addiction.
Cleve Clin J Med. 2017 May;84(5):377-384. doi: 10.3949/ccjm.84a.16091.
引用本文的文献
1
Association of economic and racial segregation with restricted buprenorphine dispensing in U.S. community pharmacies.
Drug Alcohol Depend Rep. 2024 Jul 14;12:100255. doi: 10.1016/j.dadr.2024.100255. eCollection 2024 Sep.
本文引用的文献
1
Examining the Primary Care Experience of Patients With Opioid Use Disorder: A Qualitative Study.
J Addict Med. 2023;17(4):401-406. doi: 10.1097/ADM.0000000000001140. Epub 2023 Jan 25.
2
Differences in buprenorphine treatment quality across physician provider specialties.
Drug Alcohol Depend. 2022 Aug 1;237:109510. doi: 10.1016/j.drugalcdep.2022.109510. Epub 2022 May 23.
3
Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements.
JAMA Netw Open. 2022 May 2;5(5):e225996. doi: 10.1001/jamanetworkopen.2022.5996.
4
Mindfulness-Oriented Recovery Enhancement vs Supportive Group Therapy for Co-occurring Opioid Misuse and Chronic Pain in Primary Care: A Randomized Clinical Trial.
JAMA Intern Med. 2022 Apr 1;182(4):407-417. doi: 10.1001/jamainternmed.2022.0033.
5
Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and Meta-analysis.
JAMA Psychiatry. 2021 Oct 1;78(10):1092-1102. doi: 10.1001/jamapsychiatry.2021.1969.
6
A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Subst Abuse Treat Prev Policy. 2020 Sep 14;15(1):69. doi: 10.1186/s13011-020-00312-3.
7
Stigma in health facilities: why it matters and how we can change it.
BMC Med. 2019 Feb 15;17(1):25. doi: 10.1186/s12916-019-1256-2.
Zotero 插件